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BRAF activating mutations involving the
β3-αC loop in V600E-negative anaplastic
pleomorphic xanthoastrocytoma
Drew Pratt1, Sandra Camelo-Piragua1, Kathryn McFadden1, Denise Leung2, Rajen Mody3, Arul Chinnaiyan1,4,
Carl Koschmann5* and Sriram Venneti1*
Anaplastic pleomorphic xanthoastrocytoma (A-PXA,
WHO grade III) is a newly defined entity with high-
grade histopathologic features and a propensity for
recurrence [6]. While PXA with low-grade histology
(WHO grade II) can harbor a recurrent valine-to-
glutamic acid (p.V600E) point mutation in BRAF in
up to 78% of cases [6], the genomic drivers of A-
PXA are poorly understood as the V600E mutation
is absent in over half of A-PXAs [4]. Alterations re-
ported to date in V600E-negative cases have in-
cluded novel BRAF fusions and copy number
alterations (Table 1).
The efficacy of therapeutic targeting oncogenically
activated kinases in BRAF-mutant cancers depends
on structural variations in the kinase domain. For
example, the BRAF V600E mutation is often sensi-
tive to kinase inhibitors such as vemurafenib, while
β3-αC deletions and non-canonical BRAF mutations
are often resistant to this small molecular inhibitor
[2]. Therefore, from a therapeutic aspect, it is im-
perative to define the spectrum of BRAF alterations
in these aggressive tumors. Here, we report two
newly identified A-PXAs with activating mutations
in the β3-αC loop of the BRAF kinase domain dis-
covered through whole-exome, whole-genome, and
transcriptome sequencing (Michigan Oncology
Sequencing Project [MI-ONCOSEQ]) [8].
The first case is a 5-year-old male presenting with
a large (11.7 × 7.3 cm) temporoparietal mass with
subfalcine and uncal herniation (Fig. 1a). Molecular
profiling revealed an oncogenic BRAF in-frame dele-
tion (p.L485_P490delinsF) located adjacent to the
β3-αC loop that results in a helix-constraining con-
formational change in the kinase domain. The sec-
ond case is a 23-year-old male with a parietal ring-
enhancing cystic mass. Sequencing revealed a novel
9 bp tandem duplication (p.V504_R506dup) in the
β3-αC loop that results in a three codon in-frame
insertion in the open reading frame (ORF) of BRAF
[see Fig. 1a-d and Online Resource for details and
representative images from both cases (Additional file 1)].
Consistently, both cases demonstrated MAPK activation
with strong expression of phospho-ERK1/2 in tumor cells
(Fig. 1g).
Both of the mutations reported here affect the β3-
αC loop in the kinase domain. To function properly,
protein kinases must maintain a level of structural
flexibility in order to switch between inactive and
active states. This conformational change involves
two regulatory regions in the catalytic domain: the
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activation segment and the αC-helix [2]. During this
process, the αC-helix undergoes an “out” to “in”
shift that facilitates interaction with the β3 strand
and initiates catalysis [2] (Fig. 1e). Case #1 demon-
strated a deletion mutation in the BRAF β3-αC loop
that results in a shortened αC-helix that constrains
the loop conformation to a constitutively kinase ac-
tive “in” state. Similar “in” state activating alterations
have been reported in other major signaling pathway
kinases including HER2 and EGFR [2]. β3-αC dele-
tion mutations render tumors resistant to small mol-
ecule inhibitors, such as vemurafenib, that bind to
and inhibit kinases with an “out” conformation, but
are ineffective against the “in” state [1, 2] (Fig. 1e,
f ). Case #2 contained a mutation in a structural
element (R-spine) of the αC-helix [9]. Mutations in
the R-spine have been shown to stabilize the active
state and result in constitutive kinase activation [3].
However, the effect of this mutation on the con-
formational state of the kinase domain remains to be
determined. Because RAF dimers are often formed
in tumors with β3-αC kinase loop alterations, RAF
dimer inhibition has been proposed as an alternative
therapy for these genetic alterations [10].
Recent reports of clinical responses in V600E-
mutated A-PXAs with BRAF “out” inhibitors [5, 7] have
been encouraging. However, selection of effective tar-
geted therapies requires a mechanistic understanding of
oncogenic kinase activation in tumors. We present two
A-PXAs that contain BRAF β3-αC loop alterations that
may not be sensitive to traditional BRAF inhibitors.
Therefore, treatment approaches for A-PXAs with or
without V600E mutations may differ depending on the
specific type of BRAF genetic alteration.
Table 1 Genomic alterations in BRAF V600E-negative anaplastic pleomorphic xanthoastrocytoma
Referencea Number
of cases
Method Alteration (s)
(cases/total tested)
Clinical outcome (s)
Mistry
et al., 2015
3 WES, aCGH CDKN2A HD (1/3)
TP53 mutation (1/2)
No individual case
data available
Phillips
et al., 2016
2 NGS Case 1: NRF1-BRAF (1/2)
Case 2: ATG7-RAF1 (1/2)
CDKN2A HD (2/2)
Case 1: GTR with recurrence,
f/u 48 months, deceased
Case 2: GTR with recurrence,
f/u 15 months, alive
Alexandrescu
et al., 2016
1b FISH, methylation
analysis (450 k)
CDKN2A HD
Gains: + 5, 7, 9q, 12p, 14q,
16q, 22q
Losses: −1, 6, 13q, 14q, 21q
GTR, no recurrence, f/u
10 months, alive
Hsiao
et al., 2017
1 WES, transcriptome TMEM106B-BRAF Resection, PFS 6 months, field
radiation, contralateral
recurrence, STR, progression,
chemo with TMZ, stable and
alive
Vaubel
et al., 2017
6 Chromosomal
microarray
(OncoScan)
Gains: + 7 (3/6), + 5 (2/6)
Losses: −22 (4/6), −14
(4/6), − 13 (3/6), − 10
(3/6), −1p (chromothripsis)
CDKN2A HD (5/6)
No individual case
data available
Korshunov
et al., 2017
20 b,c Methylation analysis
(450 k), targeted
sequencing
TERT c.-124C > T (5/20);
CDKN2A HD (8/20)
No individual case
data available
Current study 2 WES, WGS,
transcriptome
Case 1: BRAF p.L485_P490delinsF;
FOXO1 p.A38T; HTR2A p.D48N;
CDKN2A HD
Case 2: BRAF p.V504_R506dup;
KAT6A p.T1210 fs (subclonal)
Gains (case 2): + 5, 6, 7, 10,
12, 15
Losses (case 1): −9, 22
Case 1: near-GTR, A9952
(carboplatin, vincristine),
f/u 6 months, alive
Case 2: subtotal resection,
chemoradiation
with TMZ, alive at last f/u
4 months post-dx
WES whole exome sequencing, aCGH array comparative genomic hybridization, NGS targeted next-generation sequencing, IHC immunohistochemistry,
FISH fluorescence in situ hybridization, WGS whole genome sequencingm, HD homozygous deletion, PM promoter methylation, GTR gross total resection,
f/u follow-up, PFS progression-free survival, STR stereotactic radiotherapy, TMZ temozolomide
asee Supplemental Material for reference citations
boverlapping cases
ccases initially diagnosed as epithelioid glioblastoma but clustered with PXA with methylome analysis
Pratt et al. Acta Neuropathologica Communications  (2018) 6:24 Page 2 of 4
Additional files
Additional file 1: Clinical details, pathologic work-up, and sequencing
methodology used in the current study. Figure S1. Additional histopath-
ology from case #1 showed characteristic eosinophilic granular bodies
(EGBs) (a) and an elevated proliferation index (Ki-67) (b). Immunohisto-
chemistry for p16 showed loss of expression in tumor cells with retained
expression in non-neoplastic cells (c, arrowhead), consistent with deletion
of the INK4a locus. Staining with mutant-specific BRAF (VE1) was negative
(d). Figure S2. Case #2 showed lipidized tumor cells and PAS-positive,
diastase-resistant EGBs (arrowheads) (a). Nuclear pleomorphism and
increased mitotic activity were seen (b, c). Neurofilament stain showing
circumscription of the tumor mass (d). BRAF V600E was negative by IHC
(e). Figure S3. MI-ONCOSEQ integrative sequencing report elements:
somatic point mutations for case #1 (a) and #2 (c). Copy number plots for
case #1 (b) and #2 (d). (DOCX 13229 kb)
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Fig. 1 A-PXA with non-V600E activating mutations affecting the β3-αC loop in BRAF. Post-contrast T1-weighted coronal MR sequence
showing a large space-occupying lesion with significant midline shift (a). Histologic sections from case #1 demonstrated pleomorphic
giant cells (b), as well as pseudopalisading necrosis (c) and increased mitotic activity (d). Illustration of conformational changes of the
β3 strand and αC helix in the kinase domain. The canonical BRAF V600E mutation results in monomeric activity and can accommodate the
oncogenic BRAF inhibitor vemurafenib, which only binds when helix αC is “out” (e). In β3-αC deletion mutations, the β3-αC loop is shortened,
effectively locking helix αC in the “in” position and conferring resistance to vemurafenib (f) (modified with permission from Trends in Cancer, 2 (12),
Foster SA, Klijn C, Malek S, Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches, p. 699–701, 2016, Supplemental
Reference [2] [Online Resource]). MAPK signaling pathway activation was confirmed with immunohistochemistry with anti-phospho-p44/42 MAPK
[Erk1/2] [Thr202/Tyr204] (g)
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